About 1020% of patients are non-responders or modest responders
Viking Therapeutics (VKTX): The pure-play GLP-1 development company reported promising Phase 2 data for its own obesity candidate, VK2735
While these medications can aid in weight loss and glycemic control, combining them with healthy eating habits and regular physical activity enhances overall results
2015;33(1 Suppl 88):S82-5
Cardiovascular outcome trials have demonstrated significant reductions in major adverse cardiovascular events with certain agents in this class (liraglutide, injectable semaglutide, and dulaglutide), leading to expanded indications for cardiovascular risk reduction
However, inhibition of FAO in the cerebrovasculature even in the presence of glucose leads to defective cation transport (Steinberg et al., 1977)